AstraZeneca vs Novartis
AstraZeneca (AZN), health care, and Novartis (NVS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Novartis is worth $301.5B on the stock market and AstraZeneca $283.9B: Novartis is valued at 6% more. AstraZeneca trades at 25.9 times earnings and Novartis at 30.5; operating margins in their latest fiscal years were 23.4% and 32.4%. Over the past year AstraZeneca's share price has moved +2.75% and Novartis's +25.1%.
Key facts
- AstraZeneca market value
- $283.9B
- Novartis market value
- $301.5B
- AstraZeneca P/E
- 25.9
- Novartis P/E
- 30.5
- AstraZeneca revenue
- $58.7BFY to 2025-12-31
- Novartis revenue
- $54.5BFY to 2025-12-31
- Superinvestors holding both
- 7
Market values as of .
| Measure | AstraZeneca | Novartis |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $283.9Blower | $301.5Bhigher |
| Revenue | $58.7Bhigher | $54.5Blower |
| Earnings | $10.2Blower | $14Bhigher |
| Employees | 96,100higher | 75,267lower |
| Total assets | $114.1Bhigher | $110.9Blower |
| Valuation | ||
| P/E | 25.9lower | 30.5higher |
| P/S | 4.8lower | 5.5higher |
| P/B | — | — |
| Dividend yield | — | — |
| Profitability | ||
| Operating margin | 23.4%lower | 32.4%higher |
| Balance sheet | ||
| Net assets | $48.7Bhigher | $46.1Blower |
| Total liabilities | $65.4Bhigher | $64.4Blower |
| Total debt | $29.6Bhigher | $28.7Blower |
| Cash on hand | $5.7Blower | $11.4Bhigher |
| Price change | ||
| Today | -0.52%lower | -0.35%higher |
| 1 year | +2.75%lower | +25.1%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (7)
- Primecap team1.8% / 0.6%
- Brandon Haley1.1% / 0.4%
- Larry Robbins0.7% / 0.3%
- Ken Fisher0.5% / 0.7%
- Andrew Spokes0.4% / 0.2%
- Dodge & Cox team<0.1% / 0.1%
- Rajiv Jain<0.1% / <0.1%
AstraZeneca only (5)
- Sarah Ketterer20.2%
- Lew Sanders1.1%
- Temasek0.4%
- Steve Cohen0.2%
- Polen Capital team<0.1%
Novartis only (6)
Percentages are each holding's share of that investor's reported portfolio (under "Both": AstraZeneca / Novartis). Who owns AZN · Who owns NVS
More on AstraZeneca
Further comparisons
AstraZeneca against its closest peers
Novartis against its closest peers
Learn
Questions and answers
Which is bigger, AstraZeneca or Novartis?
By market value, Novartis is the larger: $301.5B against $283.9B for AstraZeneca. By revenue in its latest fiscal year, AstraZeneca is the larger: $58.7B against $54.5B for Novartis.
Which has the higher P/E ratio?
Novartis: 30.5, against 25.9 for AstraZeneca. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Novartis: 32.4%, against 23.4% for AstraZeneca. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has more debt?
AstraZeneca: $29.6B, against $28.7B for Novartis. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both AstraZeneca and Novartis?
In their latest 13F filings, Primecap team, Brandon Haley, Larry Robbins, Ken Fisher, Andrew Spokes, Dodge & Cox team and Rajiv Jain hold both.
Cite this page
Funkfolio, “AstraZeneca vs Novartis”, data as of 17 November 2026. https://funkfolio.com/compare/azn-vs-nvs
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.